Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.80 |
| ▸ | DRD3 | P35462 | 3/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teludipine SCHEMBL9681046 | 1.00 | SLC6A2 (0.80) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| Teludipine SCHEMBL122110 | 0.99 | SLC6A2 (0.79) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| Teludipine SCHEMBL9680668 | 0.99 | SLC6A2 (0.79) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| SCHEMBL9682241 | 0.97 | ADORA3 (0.75) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| SCHEMBL9681754 | 0.91 | SLC6A2 (0.78) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| SCHEMBL9680055 | 0.90 | SLC6A2 (0.85) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| SCHEMBL9680051 | 0.90 | SLC6A2 (0.85) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| Lacidipine SCHEMBL29352892 | 0.90 | CYP2C9 (1.00) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| Lacidipine SCHEMBL49277 | 0.90 | CYP2C9 (1.00) | SLC6A2DRD3KCNH2ADORA3OPRK1 | |
| Lacidipine SCHEMBL49278 | 0.90 | CYP2C9 (1.00) | SLC6A2DRD3KCNH2ADORA3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY INC (US) | 2025-05-15 | — | — | US | claimed |
| EP-4472637-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | Kura Oncology, Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2023-10-19 | — | — | US | claimed |
| EP-4225296-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | Insphero AG (CH) | 2023-08-16 | — | — | EP | claimed |
| WO-2023150635-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | KURA ONCOLOGY, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2022074057-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | INSPHERO AG (CH) | 2022-04-14 | — | — | WO | claimed |
| EP-3981401-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR PREVENTION OF DIABETES COMPRISING A CALCIUM CHANNEL BLOCKING AGENT AND AN INCRETIN MIMETIC | InSphero AG (CH) | 2022-04-13 | — | — | EP | claimed |
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009140527-A1 | MODIFIED RELEASE FORMULATIONS OF DIHYDROPYRIDINE COMPOUNDS AND METHODS OF MAKING SAME | CAPRICORN PHARMA, INC. (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090285889-A1 | MODIFIED RELEASE FORMULATIONS OF DIHYDROPYRIDINE COMPOUNDS AND METHODS OF MAKING SAME | CAPRICOM PHARMA INC. (US) | 2009-11-19 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152591-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS | MEN1, ABCB1, ABCC1 | SLC6A2 988/4885DRD3 4667/4885KCNH2 3575/4885 |
| US-20230330188-A1 | PHARMACEUTICAL COMBINATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF DIABETES | IAPP, SLC5A2, GLP1R | SLC6A2 533/4885DRD3 2327/4885KCNH2 122/4885 |
| US-20090285889-A1 | MODIFIED RELEASE FORMULATIONS OF DIHYDROPYRIDINE COMPOUNDS AND METHODS OF MAKING SAME | QDPR, DPYD, SRI | SLC6A2 101/4885DRD3 438/4885KCNH2 968/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | SLC6A2 564/4885DRD3 243/4885KCNH2 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.